Developer docs
API playgroundTry for free, no card

Search company profiles

Target ALS Foundation

Full company profile

uuid0009e3c

Namestring
Target ALS Foundation
Legal namestring
Target ALS Foundation, Inc.
Websiteurl
targetals.org
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Target ALS Foundation, Inc. is a 501(c)(3) nonprofit medical research foundation founded in 2013 by Dan Doctoroff and headquartered in New York City. The organization addresses systemic barriers in amyotrophic lateral sclerosis (ALS) research through a three-pillar "Innovation Ecosystem" model: (1) Fund — competitive grant programs supporting collaborative consortia, individual investigators, Springboard Fellowships, and in vivo target validation; (2) Enable — six open-access Research Cores (Genomics, Longitudinal Biofluids, Human Postmortem Tissue, Stem Cell, Reagents, and Animal Models) and the Target ALS Data Engine, a multi-omic data platform built with DNAstack and Verily Workbench; and (3) Conduct — the ALS Global Research Initiative (AGRI), comprising the Global Natural History Study and Community-Based Pop-Up Clinics across 15 active global sites.

To date, Target ALS has invested more than $80 million across 750+ research grants; 58% of funded consortia have advanced to drug discovery programs and 13 clinical trials have emerged. The Data Engine hosts the largest collection of PacBio HiFi long-read sequencing data for ALS alongside short-read whole genomes, RNA sequencing, and biofluid proteomics (CSF and plasma), with no IP restrictions on access. Strategic technology partners include DNAstack, Verily, PacBio, New York Genome Center, Psomagen, Biospective, and the Jackson Laboratory; co-funders include Gates Ventures, the Alzheimer's Drug Discovery Foundation, and The ALS Association. The annual meeting convenes 960+ attendees from academia, pharma, biotech, and nonprofits.

The organization is funded entirely through donations from individuals, foundations, and corporate sponsors, with 100% of contributions directed to research programs. Beneficiaries include people with ALS and their families (especially underrepresented populations, with 36% non-Caucasian enrollment in AGRI versus ~5% historically), academic researchers, and biotech/pharma drug developers — the latter representing more than 100 companies actively pursuing ALS assets. The organization is governed by a board that added actor Eric Dane in December 2025. Operations are lean at 1–10 employees, with scientific execution distributed through partner CROs, academic cores, and the NINDS repository.

Short descriptiontext

Target ALS Foundation is a New York-based 501(c)(3) nonprofit that operates an ALS research Innovation Ecosystem combining competitive grant funding, six open-access Research Cores, the Target ALS Data Engine, and the multi-site ALS Global Research Initiative (AGRI) to accelerate drug discovery for people with ALS.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ALS research funding, medical research foundation, neurodegenerative disease research, biospecimen repositories, multi-omics data platform
Industry2 codes
PRIMARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYBPAGAKAI
Research & Science Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
NAICS code3 codes
  • Grantmaking Foundations813211
  • Voluntary Health Organizations813212
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Medical Research Foundation
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Donations and Charitable Contributions
TypeGrants Donations
Description

Target ALS operates as a 501(c)(3) public charity (EIN: 81-0756743) funded entirely through donations from individuals, foundations, and corporate sponsors. The organization states that 100% of donations support their mission to break down barriers to ALS research.

targetals.org
2Corporate Sponsorship
TypeGrants Donations
Description

Corporate sponsorship opportunities for the Target ALS Annual Meeting, which brings together over 900 global leaders in ALS research from academia, biotech, and industry.

targetals.org
3Campaign Fundraising
TypeGrants Donations
Description

Time-limited fundraising campaigns such as the 'All In For ALS Awareness' campaign for ALS Awareness Month, inviting patients, researchers, doctors, and the public to raise visibility and funding for ALS research.

prnewswire.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 of 2 records shown
1AGRI (ALS Global Research Initiative)
Description

The most comprehensive and inclusive global effort for ALS research, encompassing the Global Natural History Study and Community-Based Pop-Up Clinics.

targetals.org
+1 more record
Core offering1 text field

Target ALS Foundation operates an Innovation Ecosystem for ALS research comprising three pillars: funding collaborative research consortia and grants, providing open-access Research Cores (biofluids, postmortem tissue, stem cells, reagents, animal models, genomics) and the Target ALS Data Engine, and conducting the ALS Global Research Initiative (AGRI) including the Global Natural History Study and Community-Based Pop-Up Clinics. All resources, biosamples, and datasets are shared with the global research community with no IP restrictions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 58% of funded consortia have led to drug discovery programs
+3 more records
Product overview1 text field

Target ALS Foundation operates the Innovation Ecosystem, a multi-component platform for ALS research acceleration comprising the ALS Global Research Initiative (AGRI) as its flagship research conduct program (including the Global Natural History Study and Community-Based Pop-Up Clinics), the Target ALS Data Engine as its open data access platform, and six Research Cores (Genomics, Longitudinal Biofluids, Human Postmortem Tissue, Stem Cell, Reagents, and Animal Models) that provide no-strings-attached access to biosamples, reagents, and tools. The organization also funds collaborative research through grant programs and hosts an annual meeting. All resources and data are shared freely with the global research community with no IP restrictions.

Product and service2 records
1ALS Global Research Initiative (AGRI)
CategoryResearch Program
Description

The most comprehensive and inclusive global ALS research initiative, encompassing the Global Natural History Study, Community-Based Pop-Up Clinics, and the Brain and Spinal Cord Donation program, addressing gaps in ALS research by enrolling diverse participants worldwide.

2Global Natural History Study
Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership16 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-10
Description

Biotechnology company awarded two-year research grant to advance SYF2 therapeutics targeting TDP-43 function, with collaboration involving Johns Hopkins University and Mayo Clinic Jacksonville.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-10
Description

Research collaborator with AcuraStem on SYF2 antisense oligonucleotide therapeutics and multiple other Target ALS-funded projects.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-10
Description

Research collaborator with AcuraStem on SYF2 therapeutics and home to Dr. Leonard Petrucelli's TDP-43 biomarker research.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Partner in biomarker initiative for ALS and FTD diagnostics accelerator alongside Target ALS and Gates Ventures.

Strategic tierCoreTypeTechnology or Integration
Description

Technology partner for the Target ALS Data Engine platform. DNAstack's technology enables integration of multi-omic datasets and provides the infrastructure for open data access to researchers worldwide.

Strategic tierCoreTypeTechnology or Integration
Description

Partner for Target ALS Data Engine, integrated with Verily Workbench for streamlined analysis of ALS datasets.

Strategic tierCoreTypeTechnology or Integration
Description

Provides PacBio HiFi long-read sequencing technology for ALS genomics research. Generates the largest collection of PacBio HiFi long-read sequencing data for ALS.

Strategic tierCoreTypeTechnology or Integration
Description

Academic partner generating Illumina-based short-read whole genomes and RNA sequencing from multiple CNS regions for the Genomics Core.

Strategic tierCoreTypeTechnology or Integration
Description

Genomics partner providing Illumina-based short-read whole genomes and Olink HT proteomics data from CSF and plasma.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Contract research organization (CRO) for in vivo target validation studies. Partners with Target ALS to evaluate novel therapeutics for target engagement and disease-modifying potential in ALS mouse models.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Provides access to 138+ ALS mouse models for preclinical research. Collaborates on in vivo target validation studies and animal model distribution.

12NINDS
Strategic tierCoreTypeStrategic or Co-development Partner
Description

National Institute of Neurological Disorders and Stroke repository for Target ALS stem cell lines. Manages banking and distribution of iPSC lines through their genetics program.

targetals.org
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partner generating MS proteomics from cerebrospinal fluid and plasma using TMTpro 35-plex methodology for the Genomics Core.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-funding partner for in vivo studies at The Jackson Laboratory testing candidate ALS therapeutics in standardized C9orf72 mouse models.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner for iPSC line generation for the Stem Cell Core. Dr. Barbara Corneo's lab creates stem cell lines from patient fibroblasts.

Strategic tierCoreTypeTechnology or Integration
Description

Partner providing access to largest collection of PacBio HiFi long-read sequencing for ALS within a global search engine for genomic variants across rare diseases.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

The largest US-based ALS nonprofit, also funding research and providing patient services. Directly competes with Target ALS for ALS research grants, donor dollars, and research partnerships; also a co-funding partner on in vivo studies at The Jackson Laboratory.

TypeDirect peer
Description

A nonprofit biotechnology research organization focused exclusively on ALS drug discovery. Operates its own lab and conducts preclinical research, making it a direct peer in the ALS translational research space.

3Project ALS
TypeDirect peer
Description

A research-focused nonprofit dedicated to funding and conducting ALS research at leading institutions. Overlapping mission around accelerating ALS therapeutics and breaking research barriers.

4The Association for Frontotemporal Degeneration (AFTD)
TypeDirect peer
Description

Nonprofit focused on frontotemporal degeneration (FTD), which shares biology with ALS. Direct peer and co-funding partner with Target ALS on $5M in 2020 grants for biomarkers and ALS/FTD treatments.

TypeDirect peer
Description

A smaller ALS research nonprofit focused on funding clinical trials and translational research. Directly comparable as a disease-specific ALS foundation competing in the same donor and grantmaking space.

TypeEmerging player
Description

Multi-institutional research consortium generating comprehensive ALS multi-omic datasets, with similar data infrastructure ambitions to Target ALS Data Engine. Partial overlap in mission to build shared ALS research resources.

TypeDirect peer
Description

Nonprofit focused on accelerating drug discovery for Alzheimer's and related dementias. Direct peer and partner in the Gates Ventures biomarker initiative covering ALS, FTD, and Alzheimer's.

TypeBroad incumbent
Description

Larger, more established neurodegenerative disease research foundation with similar model of grantmaking, research resources, and patient engagement. Comparable approach in building research infrastructure for a single disease.

TypeBroad incumbent
Description

Highly successful disease-specific research foundation that pioneered a model of directly funding drug development, including biotech venture philanthropy. Provides a comparable blueprint for scaling disease research infrastructure.

TypeEmerging player
Description

Smaller rare disease research foundation supporting basic and applied research. Comparable model of funding collaborative neuroscience research and convening research consortia.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration7 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment4 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Target ALS Foundation

Medical Research Foundationtargetals.org

Target ALS Foundation is a New York-based 501(c)(3) nonprofit that operates an ALS research Innovation Ecosystem combining competitive grant funding, six open-access Research Cores, the Target ALS Data Engine, and the multi-site ALS Global Research Initiative (AGRI) to accelerate drug discovery for people with ALS.

What Target ALS Foundation does

Target ALS Foundation, Inc. is a 501(c)(3) nonprofit medical research foundation founded in 2013 by Dan Doctoroff and headquartered in New York City. The organization addresses systemic barriers in amyotrophic lateral sclerosis (ALS) research through a three-pillar "Innovation Ecosystem" model: (1) Fund — competitive grant programs supporting collaborative consortia, individual investigators, Springboard Fellowships, and in vivo target validation; (2) Enable — six open-access Research Cores (Genomics, Longitudinal Biofluids, Human Postmortem Tissue, Stem Cell, Reagents, and Animal Models) and the Target ALS Data Engine, a multi-omic data platform built with DNAstack and Verily Workbench; and (3) Conduct — the ALS Global Research Initiative (AGRI), comprising the Global Natural History Study and Community-Based Pop-Up Clinics across 15 active global sites.

To date, Target ALS has invested more than $80 million across 750+ research grants; 58% of funded consortia have advanced to drug discovery programs and 13 clinical trials have emerged. The Data Engine hosts the largest collection of PacBio HiFi long-read sequencing data for ALS alongside short-read whole genomes, RNA sequencing, and biofluid proteomics (CSF and plasma), with no IP restrictions on access. Strategic technology partners include DNAstack, Verily, PacBio, New York Genome Center, Psomagen, Biospective, and the Jackson Laboratory; co-funders include Gates Ventures, the Alzheimer's Drug Discovery Foundation, and The ALS Association. The annual meeting convenes 960+ attendees from academia, pharma, biotech, and nonprofits.

The organization is funded entirely through donations from individuals, foundations, and corporate sponsors, with 100% of contributions directed to research programs. Beneficiaries include people with ALS and their families (especially underrepresented populations, with 36% non-Caucasian enrollment in AGRI versus ~5% historically), academic researchers, and biotech/pharma drug developers — the latter representing more than 100 companies actively pursuing ALS assets. The organization is governed by a board that added actor Eric Dane in December 2025. Operations are lean at 1–10 employees, with scientific execution distributed through partner CROs, academic cores, and the NINDS repository.

Target ALS Foundation firmographics

Firmographics
Name
Target ALS Foundation
Legal name
Target ALS Foundation, Inc.
Website
https://targetals.org
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Target ALS Foundation is a New York-based 501(c)(3) nonprofit that operates an ALS research Innovation Ecosystem combining competitive grant funding, six open-access Research Cores, the Target ALS Data Engine, and the multi-site ALS Global Research Initiative (AGRI) to accelerate drug discovery for people with ALS.
Ownership category
akta.pro rank

Target ALS Foundation industry classification

Industry
Product category
Medical Research Foundation
NAICS
Grantmaking Foundations (813211), Voluntary Health Organizations (813212), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYBPAGAKAI
Research & Science Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking

Keywords

  • ALS research funding
  • Medical research foundation
  • Neurodegenerative disease research
  • Biospecimen repositories
  • Multi-omics data platform

Where Target ALS Foundation is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Target ALS Foundation business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Donations and Charitable Contributions: Target ALS operates as a 501(c)(3) public charity (EIN: 81-0756743) funded entirely through donations from individuals, foundations, and corporate sponsors. The organization states that 100% of donations support their mission to break down barriers to ALS research.
  2. Corporate Sponsorship: Corporate sponsorship opportunities for the Target ALS Annual Meeting, which brings together over 900 global leaders in ALS research from academia, biotech, and industry.
  3. Campaign Fundraising: Time-limited fundraising campaigns such as the 'All In For ALS Awareness' campaign for ALS Awareness Month, inviting patients, researchers, doctors, and the public to raise visibility and funding for ALS research.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Target ALS Foundation product offering

Product offering

Core offering

Target ALS Foundation operates an Innovation Ecosystem for ALS research comprising three pillars: funding collaborative research consortia and grants, providing open-access Research Cores (biofluids, postmortem tissue, stem cells, reagents, animal models, genomics) and the Target ALS Data Engine, and conducting the ALS Global Research Initiative (AGRI) including the Global Natural History Study and Community-Based Pop-Up Clinics. All resources, biosamples, and datasets are shared with the global research community with no IP restrictions.

Product overview

Target ALS Foundation operates the Innovation Ecosystem, a multi-component platform for ALS research acceleration comprising the ALS Global Research Initiative (AGRI) as its flagship research conduct program (including the Global Natural History Study and Community-Based Pop-Up Clinics), the Target ALS Data Engine as its open data access platform, and six Research Cores (Genomics, Longitudinal Biofluids, Human Postmortem Tissue, Stem Cell, Reagents, and Animal Models) that provide no-strings-attached access to biosamples, reagents, and tools. The organization also funds collaborative research through grant programs and hosts an annual meeting. All resources and data are shared freely with the global research community with no IP restrictions.

Differentiator

Problem solved

Functional benefit

Brands

  • AGRI (ALS Global Research Initiative): The most comprehensive and inclusive global effort for ALS research, encompassing the Global Natural History Study and Community-Based Pop-Up Clinics.
  • Target ALS Data Engine

Products and services

  • ALS Global Research Initiative (AGRI) The most comprehensive and inclusive global ALS research initiative, encompassing the Global Natural History Study, Community-Based Pop-Up Clinics, and the Brain and Spinal Cord Donation program, addressing gaps in ALS research by enrolling diverse participants worldwide.
  • Global Natural History Study

Quantifiable outcome

  • 58% of funded consortia have led to drug discovery programs
  • +3 more outcomes

Companies that use Target ALS Foundation

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Target ALS Foundation technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration7 records

AI capability5 records

Feature6 records

Target ALS Foundation partnerships and signals

Strategic signal

Partnerships

16 partnerships are on record, tiered core and major.

  • AcuraStemcoreStrategic or Co-development Partner · 10 March 2026Biotechnology company awarded two-year research grant to advance SYF2 therapeutics targeting TDP-43 function, with collaboration involving Johns Hopkins University and Mayo Clinic Jacksonville.
  • Johns Hopkins UniversitycoreStrategic or Co-development Partner · 10 March 2026Research collaborator with AcuraStem on SYF2 antisense oligonucleotide therapeutics and multiple other Target ALS-funded projects.
  • Mayo Clinic JacksonvillecoreStrategic or Co-development Partner · 10 March 2026Research collaborator with AcuraStem on SYF2 therapeutics and home to Dr. Leonard Petrucelli's TDP-43 biomarker research.
  • Alzheimer's Drug Discovery FoundationmajorStrategic or Co-development Partner · 1 January 2022Partner in biomarker initiative for ALS and FTD diagnostics accelerator alongside Target ALS and Gates Ventures.
  • DNAstackcoreTechnology or IntegrationTechnology partner for the Target ALS Data Engine platform. DNAstack's technology enables integration of multi-omic datasets and provides the infrastructure for open data access to researchers worldwide.
  • VerilycoreTechnology or IntegrationPartner for Target ALS Data Engine, integrated with Verily Workbench for streamlined analysis of ALS datasets.
  • PacBiocoreTechnology or IntegrationProvides PacBio HiFi long-read sequencing technology for ALS genomics research. Generates the largest collection of PacBio HiFi long-read sequencing data for ALS.
  • New York Genome CentercoreTechnology or IntegrationAcademic partner generating Illumina-based short-read whole genomes and RNA sequencing from multiple CNS regions for the Genomics Core.
  • PsomagencoreTechnology or IntegrationGenomics partner providing Illumina-based short-read whole genomes and Olink HT proteomics data from CSF and plasma.
  • BiospectivecoreImplementation/ SI/ Consulting PartnerContract research organization (CRO) for in vivo target validation studies. Partners with Target ALS to evaluate novel therapeutics for target engagement and disease-modifying potential in ALS mouse models.
  • The Jackson LaboratorycoreImplementation/ SI/ Consulting PartnerProvides access to 138+ ALS mouse models for preclinical research. Collaborates on in vivo target validation studies and animal model distribution.
  • NINDScoreStrategic or Co-development PartnerNational Institute of Neurological Disorders and Stroke repository for Target ALS stem cell lines. Manages banking and distribution of iPSC lines through their genetics program.
  • University of Gothenburg (Henrik Zetterberg team)coreStrategic or Co-development PartnerAcademic partner generating MS proteomics from cerebrospinal fluid and plasma using TMTpro 35-plex methodology for the Genomics Core.
  • The ALS AssociationcoreStrategic or Co-development PartnerCo-funding partner for in vivo studies at The Jackson Laboratory testing candidate ALS therapeutics in standardized C9orf72 mouse models.
  • Columbia University Irving Medical CentercoreStrategic or Co-development PartnerPartner for iPSC line generation for the Stem Cell Core. Dr. Barbara Corneo's lab creates stem cell lines from patient fibroblasts.
  • HiFi SolvescoreTechnology or IntegrationPartner providing access to largest collection of PacBio HiFi long-read sequencing for ALS within a global search engine for genomic variants across rare diseases.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Target ALS Foundation competitors and assessment

Company assessment

Direct peers

  • The ALS Association: The largest US-based ALS nonprofit, also funding research and providing patient services. Directly competes with Target ALS for ALS research grants, donor dollars, and research partnerships; also a co-funding partner on in vivo studies at The Jackson Laboratory.
  • ALS Therapy Development Institute (ALS TDI): A nonprofit biotechnology research organization focused exclusively on ALS drug discovery. Operates its own lab and conducts preclinical research, making it a direct peer in the ALS translational research space.
  • Project ALS: A research-focused nonprofit dedicated to funding and conducting ALS research at leading institutions. Overlapping mission around accelerating ALS therapeutics and breaking research barriers.
  • The Association for Frontotemporal Degeneration (AFTD): Nonprofit focused on frontotemporal degeneration (FTD), which shares biology with ALS. Direct peer and co-funding partner with Target ALS on $5M in 2020 grants for biomarkers and ALS/FTD treatments.
  • ALS Hope Foundation: A smaller ALS research nonprofit focused on funding clinical trials and translational research. Directly comparable as a disease-specific ALS foundation competing in the same donor and grantmaking space.
  • Alzheimer's Drug Discovery Foundation (ADDF): Nonprofit focused on accelerating drug discovery for Alzheimer's and related dementias. Direct peer and partner in the Gates Ventures biomarker initiative covering ALS, FTD, and Alzheimer's.

Emerging players

  • Answer ALS: Multi-institutional research consortium generating comprehensive ALS multi-omic datasets, with similar data infrastructure ambitions to Target ALS Data Engine. Partial overlap in mission to build shared ALS research resources.
  • Hereditary Disease Foundation: Smaller rare disease research foundation supporting basic and applied research. Comparable model of funding collaborative neuroscience research and convening research consortia.

Broad incumbents

  • Michael J. Fox Foundation for Parkinson's Research: Larger, more established neurodegenerative disease research foundation with similar model of grantmaking, research resources, and patient engagement. Comparable approach in building research infrastructure for a single disease.
  • Cystic Fibrosis Foundation: Highly successful disease-specific research foundation that pioneered a model of directly funding drug development, including biotech venture philanthropy. Provides a comparable blueprint for scaling disease research infrastructure.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Target ALS Foundation social profiles

Digital presence

Target ALS Foundation compliance and trust

Trust signal

Compliance1 record

Target ALS Foundation financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Target ALS Foundation leadership team

Management profile

Number of profiles

Profiles6 records

Target ALS Foundation funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Target ALS Foundation M&A and investment

M&A and investment

M&A

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Target ALS Foundation

What does Target ALS Foundation do?

Target ALS Foundation operates an Innovation Ecosystem for ALS research comprising three pillars: funding collaborative research consortia and grants, providing open-access Research Cores (biofluids, postmortem tissue, stem cells, reagents, animal models, genomics) and the Target ALS Data Engine, and conducting the ALS Global Research Initiative (AGRI) including the Global Natural History Study and Community-Based Pop-Up Clinics. All resources, biosamples, and datasets are shared with the global research community with no IP restrictions.

Is Target ALS Foundation a public or private company?

Target ALS Foundation is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Target ALS Foundation founded?

Target ALS Foundation was founded in 2013. It employs 11 to 50 people.

Where is Target ALS Foundation based?

Target ALS Foundation is headquartered in New York, United States, in the North America region.

How does Target ALS Foundation make money?

Three revenue lines are on record. Donations and Charitable Contributions are the primary driver. The others are corporate Sponsorship and campaign Fundraising.

Who are Target ALS Foundation's main competitors?

Direct peers on record are The ALS Association, ALS Therapy Development Institute (ALS TDI), Project ALS, The Association for Frontotemporal Degeneration (AFTD), ALS Hope Foundation and Alzheimer's Drug Discovery Foundation (ADDF). Emerging players are Answer ALS and Hereditary Disease Foundation. Broad incumbents are Michael J. Fox Foundation for Parkinson's Research and Cystic Fibrosis Foundation.

Does Target ALS Foundation have an API?

No public API is recorded for Target ALS Foundation.

What industry is Target ALS Foundation in?

Target ALS Foundation's product category is Medical Research Foundation. Its primary akta.pro industry code is BPAGACAA, Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS), with a secondary code of BPAGAKAI, Research & Science Grantmaking Foundations. Its NAICS code is 813211 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TargetalsBuilding the Data Foundation for AI-Driven ALS Drug DiscoveryTarget ALS described its data infrastructure for AI-driven ALS drug discovery, including the 2024 Data Engine, which centralizes multimodal clinical, demographic, and biological datasets, and Research Cores offering matched biosamples. The platform is freely available to researchers, with access within 48 hours of a no-strings-attached agreement, and is used by over 660 researchers across 35 countries.PR NewswireAre You All In? Target ALS Goes "All In For ALS Awareness" with Campaign to Highlight the Community and Research Building a World Where Everyone LivesTarget ALS has launched its 'All In For ALS Awareness' campaign for ALS Awareness Month in May 2026, inviting patients, researchers, doctors, and the public to raise visibility and funding for ALS research. The campaign focuses on community storytelling, donations, and fundraising to accelerate scientific progress against ALS, an incurable degenerative disease with a two-to-five year life expectancy. Target ALS, a medical research foundation established in 2013, emphasizes its disruptive fund-enable-conduct model and the ALS Global Research Initiative as drivers of worldwide collaboration to find effective treatments.TargetalsQ1 2026 Research SpotlightsTarget ALS highlighted QurAlis' positive interim data from its ANQUR trial for QRL-201, a therapeutic targeting STATHMIN-2 expression in ALS patients. The organization also announced a new three-year precompetitive consortium led by Vlaams Instituut voor Biotechnologie (VIB) to investigate C9orf72-related ALS and FTD mechanisms.PR NewswireEric Dane joins Target ALS Board of Directors to Help Scale Organization's Impact on ALS ResearchActor Eric Dane has joined the Board of Directors at Target ALS, a medical research foundation dedicated to accelerating treatments for Amyotrophic Lateral Sclerosis. This appointment underscores his continued advocacy and commitment to the organization's mission following his own diagnosis in November 2024. Target ALS aims to leverage this leadership addition to further scale its impact on global ALS research efforts.TargetalsFunded ProjectsTarget ALS, a non-profit research foundation, has awarded grants across the full spectrum of ALS research, with 41% of funding directed toward understanding ALS biology, 25% toward accelerating drug discovery, and 33% toward developing biomarkers for earlier diagnosis and disease tracking. Since inception, the organization has funded 78 consortia receiving approximately $59.3 million in grants through collaborative consortia, individual investigator grants, springboard fellowships, and in vivo target validation programs. The funded projects span from 2016 through 2025 and include academic-industry partnerships across multiple therapeutic approaches including antisense oligonucleotides, CRISPR gene therapy, small molecules, and antibody therapeutics targeting TDP-43 pathology, C9orf72 ALS, and other ALS subtypes.PR NewswireEric Dane joins Target ALS for "Ending ALS Starts With You" Campaign to raise $500,000 for ALS ResearchActor Eric Dane has partnered with Target ALS, a nonprofit focused on breaking down barriers to ALS research, to launch the 'Ending ALS Starts With You' campaign aimed at raising $500,000 by December 31, 2025. Dane, who was diagnosed with ALS in November 2024, is using his platform to amplify the organization's mission and has connected with Target ALS founder Dan Doctoroff, also living with ALS, to support the cause. Target ALS has invested more than $80 million in ALS research to date, funding over 750 grants and supporting 11 clinical trials and six biotech companies.PR NewswireALS NETWORK PARTNERS WITH TARGET ALS TO ACCELERATE GLOBAL ALS RESEARCH EFFORTSThe ALS Network has partnered with Target ALS to advance global ALS research through a collaborative program that funds breakthrough projects at leading institutions worldwide. The partnership combines the missions of both organizations to accelerate ALS drug discovery and support early-career scientists. Nine research projects have been selected for funding, spanning biomarkers, liquid biopsies, and potential therapies targeting TDP-43 pathology and C9orf72-linked ALS.VerilyTrusted Research Environment (TRE)Verily Workbench is a secure research platform designed to facilitate the discovery, sharing, and analysis of multimodal health data for pharma, biotech, and academic researchers. The platform supports AI/ML development by providing integrated GPU/TPU infrastructure and governance tools, with recent collaborations including partnerships with NVIDIA for AI acceleration and Target ALS for data access.PR NewswireTarget ALS Launches "Behind Every Breakthrough" Campaign for ALS Awareness Month to Spotlight Progress and People Driving ALS Research ForwardTarget ALS has launched "Behind Every Breakthrough," a month-long multimedia campaign for ALS Awareness Month in May 2025 that spotlights global progress in ALS research and the individuals driving it forward. The organization, founded by Dan Doctoroff—who was diagnosed with ALS in 2021 after losing both his father and uncle to the disease—has helped launch 10 clinical trials and numerous drug discovery programs since 2013. The campaign coincides with Target ALS's largest annual meeting (May 6–8 in Boston) and the ALS Global Research Initiative, which aims to expand research diversity through community-based clinics and data collection.YahooTarget ALS Highlighted in New Case Study Released by Harvard Kennedy School Focused on Innovative Model for Collaborative Medical ResearchHarvard Kennedy School released a case study on Dan Doctoroff and Target ALS, examining how collaboration and funding models accelerate ALS research. The study highlights Doctoroff's leadership in breaking down silos and uniting academia and industry. It will be used as a resource for students and executives.